Filing search / Kineta, Inc. / "Benefits"

8-K

EX-99.1

KANT Kineta, Inc.

8 Oct 24

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

9:05am

statements. These forward-looking statements include, without limitation, statements relating to the anticipated benefits of the Agreement and statements … trials of Kineta or its collaborators; the clinical utility, potential benefits and market acceptance of Kineta’s product candidates; Kineta’s

8-K

EX-99.1

KANT Kineta, Inc.

4 Oct 24

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

9:05am

to the anticipated benefits of the Agreement and statements relating to Kineta’s exploration of strategic alternatives and reinitiation of the VISTA-101 Phase 1 … of cessation or delay of any ongoing or planned clinical trials of Kineta or its collaborators; the clinical utility, potential benefits and market

8-K

EX-99.1

KANT Kineta, Inc.

2 Oct 24

Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid tumor cancer

4:07pm

statements. These forward-looking statements include, without limitation, statements relating to the anticipated benefits of the Exclusivity and Right … or delay of any ongoing or planned clinical trials of Kineta or its collaborators; the clinical utility, potential benefits and market acceptance

8-K

EX-99.1

KANT Kineta, Inc.

19 Sep 24

Other Events

9:53pm

to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to the anticipated benefits … of any ongoing or planned clinical trials of Kineta or its collaborators; the clinical utility, potential benefits and market acceptance of Kineta’s

8-K

EX-99.1

KANT Kineta, Inc.

19 Aug 24

Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

9:01am

statements include, without limitation, statements relating to the anticipated benefits of the Agreement and statements relating to Kineta’s … collaborators; the clinical utility, potential benefits and market acceptance of Kineta’s product candidates; Kineta’s commercialization, marketing

8-K

EX-99.1

rejri9j lnn0

8 Jul 24

Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences

6:30am

8-K

EX-99.1

14cwa4gzsh

15 May 24

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

4:03pm

8-K

EX-99.1

kcjvg

8 Apr 24

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

4:02pm

8-K

EX-99.1

skc q67tau

21 Mar 24

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

4:04pm

8-K

vnue4h6jthz4s

12 Mar 24

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

8:05am

8-K

EX-99.2

26tpua6wsmnph5ln

12 Mar 24

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

8:05am

8-K

EX-99.1

tms9gs l650cgod97

12 Mar 24

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

8:05am

8-K

qhlqtkft

29 Feb 24

Kineta Announces Restructuring and Exploration of Strategic Alternatives

7:00am

8-K

EX-10.1

u9rxrd

29 Feb 24

Kineta Announces Restructuring and Exploration of Strategic Alternatives

7:00am

8-K

EX-10.2

98bgtjeufik6de7i8

29 Feb 24

Kineta Announces Restructuring and Exploration of Strategic Alternatives

7:00am